Ipsen   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boulogne France (1929)

Organization Overview

First Clinical Trial
1990
NCT00571727
First Marketed Drug
2005
mecasermin (increlex)
First NDA Approval
2007
lanreotide (somatuline depot)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Biomeasure Inc, Ipsen Group | Ipsen | Ipsen Biopharmaceuticals | IPSEN BIOPHARM LTD | Ipsen (formerly Tercica) | Ipsen (formerly Tercica, Inc.) | IPSEN INC | Ipsen Innovation | IPSEN PHARMA | IPSEN pharmaceutical company, Boulogne-Billancourt, France | IPSEN PHARMA S.A.S